Published in Eur J Health Econ on May 16, 2014
Cost-of-illness in patients with moderate to severe psoriasis: a cross-sectional survey in Hungarian dermatological centres. Eur J Health Econ (2014) 0.75
Severity and management of psoriasis within primary care. BMC Fam Pract (2016) 0.75
How is disease severity associated with quality of life in psoriasis patients? Evidence from a longitudinal population-based study in Sweden. Health Qual Life Outcomes (2017) 0.75
Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L in psoriasis patients. Qual Life Res (2017) 0.75
A power primer. Psychol Bull (1992) 63.66
Modeling valuations for EuroQol health states. Med Care (1997) 21.66
Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. Clin Exp Dermatol (1994) 10.17
Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol (2012) 4.52
A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures. Eur J Health Econ (2009) 2.91
Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis. J Am Acad Dermatol (2011) 2.63
The Dermatology Life Quality Index 1994-2007: a comprehensive review of validation data and clinical results. Br J Dermatol (2008) 2.53
Quality of life in patients with psoriasis: a systematic literature review. J Investig Dermatol Symp Proc (2004) 1.95
Cross-cultural inequivalence of dermatology-specific health-related quality of life instruments in psoriasis patients. J Invest Dermatol (2007) 1.64
10 years experience of the Dermatology Life Quality Index (DLQI). J Investig Dermatol Symp Proc (2004) 1.58
The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study. Health Qual Life Outcomes (2006) 1.31
Age, gender, quality of life and psychological distress in patients hospitalized with psoriasis. Br J Dermatol (2006) 1.28
Review of studies mapping from quality of life or clinical measures to EQ-5D: an online database. Health Qual Life Outcomes (2013) 1.27
Living with psoriasis: prevalence of shame, anger, worry, and problems in daily activities and social life. Acta Derm Venereol (2012) 1.22
What are the best outcome measures for assessing quality of life in plaque type psoriasis? A systematic review of the literature. J Eur Acad Dermatol Venereol (2010) 1.10
Gender and the treatment of immune-mediated chronic inflammatory diseases: rheumatoid arthritis, inflammatory bowel disease and psoriasis: an observational study. BMC Med (2012) 1.03
Patients with palmoplantar psoriasis have more physical disability and discomfort than patients with other forms of psoriasis: implications for clinical practice. J Am Acad Dermatol (2003) 0.94
Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies. J Eur Acad Dermatol Venereol (2013) 0.93
Mapping from disease-specific to generic health-related quality-of-life scales: a common factor model. Value Health (2012) 0.91
Analysis of three outcome measures in moderate to severe psoriasis: a registry-based study of 2450 patients. Br J Dermatol (2012) 0.90
Reliability and validity of the psoriasis symptom inventory in patients with moderate-to-severe psoriasis. J Dermatolog Treat (2013) 0.85
Cost effectiveness of biologic therapies for plaque psoriasis. Am J Clin Dermatol (2013) 0.83
Mapping DLQI on EQ-5D in psoriasis: transformation of skin-specific health-related quality of life into utilities. Arch Dermatol Res (2012) 0.82
Impact of active and stable psoriasis on health-related quality of life: the PSO-LIFE study. Actas Dermosifiliogr (2013) 0.80
Are treatment satisfaction, quality of life, and self-assessed disease severity relevant parameters for patient registries? Experiences from Finnish and Swedish patients with psoriasis. Acta Derm Venereol (2011) 0.79
Psoriasis affects patient's quality of life more seriously in female than in male in Japan. Tokai J Exp Clin Med (2012) 0.78
Comparison of the Psoriatic Arthritis Quality of Life (PsAQoL) questionnaire, the functional status (HAQ) and utility (EQ-5D) measures in psoriatic arthritis: results from a cross-sectional survey. Scand J Rheumatol (2010) 0.78
Validation of a new tool to assess health-related quality of life in psoriasis: the PSO-LIFE questionnaire. Health Qual Life Outcomes (2012) 0.78
Cost-of-illness in patients with moderate to severe psoriasis: a cross-sectional survey in Hungarian dermatological centres. Eur J Health Econ (2014) 0.75
Epidermal transglutaminase (TGase 3) is the autoantigen of dermatitis herpetiformis. J Exp Med (2002) 1.75
Impact of effective tumor necrosis factor-alfa inhibitor treatment on arterial intima-media thickness in psoriasis: results of a pilot study. J Am Acad Dermatol (2013) 1.60
The burden of endometriosis: costs and quality of life of women with endometriosis and treated in referral centres. Hum Reprod (2012) 1.47
Does dermatitis herpetiformis result in bone loss as coeliac disease does? A cross sectional study. Rev Esp Enferm Dig (2013) 1.40
Three novel mutations in the ATP2A2 gene in Hungarian families with Darier's disease, including a novel splice site generating intronic nucleotide change. J Dermatol Sci (2005) 1.39
[Survey of adults living with epilepsy in Hungary: health-related quality of life and costs]. Ideggyogy Sz (2013) 1.38
Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries. Eur J Health Econ (2014) 1.26
Changes in equity in out-of-pocket payments during the period of health care reforms: evidence from Hungary. Int J Equity Health (2012) 1.21
User fees for public health care services in Hungary: expectations, experience, and acceptability from the perspectives of different stakeholders. Health Policy (2011) 1.12
Peripheral blood gene expression patterns discriminate among chronic inflammatory diseases and healthy controls and identify novel targets. BMC Med Genomics (2010) 1.09
Adherence to biologic DMARD therapies in rheumatoid arthritis. Expert Opin Biol Ther (2010) 1.06
Biological therapy in inflammatory rheumatic diseases: issues in Central and Eastern European countries. Eur J Health Econ (2014) 0.99
Delphi approach to select rare diseases for a European representative survey. The BURQOL-RD study. Health Policy (2012) 0.97
IgA autoantibodies in the pemphigoids and linear IgA bullous dermatosis. Exp Dermatol (2010) 0.96
Comèl-Netherton syndrome and peeling skin syndrome type B: overlapping syndromes or one entity? Int J Dermatol (2002) 0.95
History of health technology assessment in Hungary. Int J Technol Assess Health Care (2009) 0.93
The disease burden of colorectal cancer in Hungary. Eur J Health Econ (2010) 0.93
Subjective expectations regarding length and health-related quality of life in Hungary: results from an empirical investigation. Health Expect (2012) 0.93
Informal payments for healthcare services and short-term effects of the introduction of visit fee on these payments in Hungary. Int J Health Plann Manage (2011) 0.93
Costs of rheumatoid arthritis in Hungary. J Rheumatol (2007) 0.93
Efficacy and safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis: a mixed treatment comparison. Eur J Health Econ (2014) 0.92
Exploring consumers' attitudes towards informal patient payments using the combined method of cluster and multinomial regression analysis--the case of Hungary. BMC Health Serv Res (2013) 0.91
Work disability and productivity loss in patients with inflammatory bowel diseases in Hungary in the era of biologics. Eur J Health Econ (2014) 0.90
Cost-of-illness of patients with systemic sclerosis in a tertiary care centre. Rheumatology (Oxford) (2010) 0.89
Establishing a standard for patient-completed instrument adaptations in Eastern Europe: experience with the Nottingham Health Profile in Hungary. Health Policy (2003) 0.89
Health technology assessment in Poland, the Czech Republic, Hungary, Romania and Bulgaria. Eur J Health Econ (2014) 0.88
Clinical and laboratory examinations in the subgroups of chronic urticaria. Int Arch Allergy Immunol (2007) 0.87
Disease burden of psoriatic arthritis compared to rheumatoid arthritis, Hungarian experiment. Rheumatol Int (2009) 0.87
Immunological and clinical effects of alphacalcidol in patients with psoriatic arthropathy: results of an open, follow-up pilot study. Acta Derm Venereol (2009) 0.84
Identification of a novel deletion in the ABCC6 gene leading to Pseudoxanthoma elasticum. J Dermatol Sci (2005) 0.84
Subjective health expectations at biological therapy initiation: a survey of rheumatoid arthritis patients and rheumatologists. Eur J Health Econ (2014) 0.84
Tissue transglutaminase ELISA positivity in autoimmune disease independent of gluten-sensitive disease. Clin Chim Acta (2006) 0.83
Patients' preferences for healthcare system reforms in Hungary: a conjoint analysis. Appl Health Econ Health Policy (2006) 0.82
Searching for foreign antigens as possible triggering factors of autoimmunity: Torque Teno virus DNA prevalence is elevated in sera of patients with bullous pemphigoid. Exp Dermatol (2008) 0.82
The link between past informal payments and willingness of the Hungarian population to pay formal fees for health care services: results from a contingent valuation study. Eur J Health Econ (2013) 0.82
Central nervous system involvement in CD4+/CD56+ hematodermic neoplasm: a report of two cases. J Neurooncol (2009) 0.81
Molecular epidemiological analysis of env and pol sequences in newly diagnosed HIV type 1-infected, untreated patients in Hungary. AIDS Res Hum Retroviruses (2011) 0.81
Serum cytokine levels and type 1 and type 2 intracellular T cell cytokine profiles in mixed connective tissue disease. J Rheumatol (2002) 0.81
[Mortality of hospitalized stroke patients in Hungary; 2003-2005]. Ideggyogy Sz (2007) 0.81
Easy method for keratin 14 gene amplification to exclude pseudogene sequences: new keratin 5 and 14 mutations in epidermolysis bullosa simplex. J Invest Dermatol (2008) 0.80
The chemokine receptor CCR3 participates in tissue remodeling during atopic skin inflammation. J Dermatol Sci (2013) 0.80
[Analysis of syphilis and gonorrhoea cases, based on data from the National STD Centre, Department of Dermatology and Venerology, Semmelweis University (2005-2008)]. Orv Hetil (2009) 0.80
Evidence for a role of autoantibodies to heat shock protein 60, 70, and 90 in patients with dermatitis herpetiformis. Cell Stress Chaperones (2014) 0.80
Association of collagenous colitis with prurigo nodularis. Eur J Gastroenterol Hepatol (2009) 0.80
Development of an ELISA for sensitive and specific detection of IgA autoantibodies against BP180 in pemphigoid diseases. Orphanet J Rare Dis (2011) 0.80
Paraffinoma. J Dtsch Dermatol Ges (2010) 0.80
Eosinophilic Fasciitis associated with Mycoplasma arginini infection. J Clin Microbiol (2011) 0.80
Experiences with tumour necrosis factor-{alpha} inhibitors in patients with juvenile idiopathic arthritis: Hungarian data from the National Institute of Rheumatology and Physiotherapy Registry. Rheumatology (Oxford) (2011) 0.80
[Priorisation in health-care; drug-reimbursement priorities in Hungary in 2004]. Acta Pharm Hung (2006) 0.79
Cost of illness of medically treated benign prostatic hyperplasia in Hungary. Int Urol Nephrol (2015) 0.79
[Impact of disease progression on health status, quality of life and costs in rheumatoid arthritis in Hungary]. Orv Hetil (2008) 0.79
Association between serum IL-16 levels and the degree of sensitization in patients with atopic dermatitis. Int Arch Allergy Immunol (2011) 0.79
The effects of extracorporeal photochemotherapy on T cell activation and regulatory mechanisms in patients with systemic sclerosis. Clin Rheumatol (2012) 0.79
UVB induces a biphasic response of HIF-1alpha in cultured human keratinocytes. Exp Dermatol (2008) 0.79
[Quality of life and burden of disease in peripheral arterial disease: a study among Hungarian patients]. Orv Hetil (2013) 0.79
Clinical, histopathological, immunophenotypic and molecular analysis of 60 patients with cutaneous T-cell infiltrates with follow up of indeterminate cases to identify T-cell lymphoma. Pathol Oncol Res (2008) 0.79
[Effectiveness of prostanoids in patients with critical leg ischemia]. Orv Hetil (2011) 0.79
Correlation between T-cell and mast cell activity in patients with chronic urticaria. Int Arch Allergy Immunol (2003) 0.79
Effects of non-toxic zinc exposure on human epidermal keratinocytes. Metallomics (2015) 0.79
The time for cost-effectiveness in the new European Union member states: the development and role of health economics and technology assessment in the mirror of the Hungarian experience. Eur J Health Econ (2007) 0.79
Tissue-specific homing of immune cells in malignant skin tumors. Pathol Oncol Res (2012) 0.78
Indeterminate cell histiocytosis in a pediatric patient: successful treatment with thalidomide. Pathol Oncol Res (2011) 0.78
Altered peripheral invariant natural killer T cells in atopic dermatitis. J Clin Immunol (2011) 0.78
Health status and costs of ambulatory patients with multiple sclerosis in Hungary. Ideggyogy Sz (2012) 0.78
Transfection of pseudouridine-modified mRNA encoding CPD-photolyase leads to repair of DNA damage in human keratinocytes: a new approach with future therapeutic potential. J Photochem Photobiol B (2013) 0.78
[The impact of endometriosis on the quality of life in Hungary]. Orv Hetil (2013) 0.78
Regulatory T-cell subsets with acquired functional impairment: important indicators of disease severity in atopic dermatitis. Acta Derm Venereol (2015) 0.78
Dirofilaria repens infection case in Hungary: a case report. J Dtsch Dermatol Ges (2006) 0.78
Genotype analysis in Hungarian patients with multiple primary melanoma. Exp Dermatol (2014) 0.78
Intravascular large B-cell lymphoma: remission after rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy. J Am Acad Dermatol (2009) 0.77
Follow-up analysis of circulating mononuclear cell CLA expression in patients with psoriasis. J Dermatol Sci (2005) 0.77
[Health related quality of life and disease burden of patients with schizophrenia in Hungary]. Psychiatr Hung (2012) 0.77